Holen Sie sich die Stockscreener-App
2.61
1.56%
0.04
Vivos Therapeutics Inc Aktie (VVOS) Neueste Nachrichten
Vivos Therapeutics Inc (VVOS) Q4 2024 Earnings Call Highlights: Strategic Shifts Propel Revenue ... By GuruFocus - Investing.com Canada
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vivos Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Vivos Therapeutics’ Earnings Call Highlights Growth and Expansion - TipRanks
Vivos Therapeutics (VVOS) Grows Revenue by 26% and Cuts Operatin - GuruFocus
Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global Partners - TipRanks
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Reports Revenue Growth and Strategic Shift - TipRanks
Vivos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Vivos Therapeutics Q4 2024 revenue rises 9% By Investing.com - Investing.com UK
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update - TradingView
Vivos Earnings: Revenue Jumps 9% as FDA Approves Game-Changing Pediatric Sleep Apnea Treatment - Stock Titan
Vivos Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Decline in Short Interest - Defense World
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - The Manila Times
Medical Device Innovator Vivos Sets Key Earnings Date: What to Watch in 2024 Results - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
The Silent Epidemic: How Women With Obstructive Sleep Apnea (OSA) Are Often Misdiagnosed - Yahoo Finance
Vivos Therapeutics (VVOS) Projected to Post Quarterly Earnings on Thursday - Defense World
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update - Defense World
Vivos Drives Innovation in Chronic Pain Care with Non-Invasive Treatment for Sleep Apnea - PRWeb
Anti-Snoring Devices Markets: Oral Appliances, Nasal - GlobeNewswire
Anti-Snoring Devices Markets: Oral Appliances, Nasal Devices, Position Control DevicesGlobal Forecast to 2029 with ResMed, SomnoMed, ProSomnus, and Vivos Therapeutics, and DynaFlex Dominating - Yahoo Finance UK
Comparing Vivos Therapeutics (NASDAQ:VVOS) and Regenicin (OTCMKTS:RGIN) - Armenian Reporter
Vivos Therapeutics Announces the Opening of the First Pneusomnia Integrated Medical-Dental Sleep Center - MarketScreener
Vivos Explores ‘Outright Acquisitions of Sleep Centers’ - Sleep Review
Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance - Proactive Investors UK
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide - The Manila Times
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and - EIN News
Reviewing Vivos Therapeutics (NASDAQ:VVOS) & Biostage (OTCMKTS:BSTG) - Defense World
Vivos Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Vivos Therapeutics to participate in Fireside Chat with Water Tower Research - Proactive Investors UK
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm - EIN News
Revolutionary Sleep Apnea Treatment: Vivos CEO Reveals Market Strategy and Medical Partnerships - Stock Titan
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding - Simply Wall St
Vivos Therapeutics Enters Into At The Market Offering Agreement with H.C. Wainwright & Co., LLC**Littleton, Colo. – Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced on February 14, 2025, that the company has entered into an At The Market Offering - Defense World
Vivos Therapeutics Enters Market Offering Agreement with Wainwright - TipRanks
Vivos Therapeutics announces up to $50M mixed shelf offering - MSN
Vivos Therapeutics Inc Files For Mixed Shelf Of Up To $50 MillionSEC Filing -February 11, 2025 at 05:44 pm EST - Marketscreener.com
Cancer Breakthrough: Vivos RadioGel Eliminates 80% of Tumor Mass in Groundbreaking Trial - Stock Titan
Trapped in CPAP Dependency? Vivos Liberates OSA Patients with Non-Invasive Solution - PR Web
Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders - MSN
Vivos Therapeutics (VVOS) Stock Price, News & Analysis - MarketBeat
VVOS Stock Price and Chart — NASDAQ:VVOS — TradingView«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Best Momentum Stocks to Buy for January 8th - MSN
Recognizing Sleep as the Sixth Vital Sign: How Vivos Is Redefining Health Care - PR Web
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 28.9% in December - Defense World
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar - Simply Wall St
Vivos Therapeutics announces $3.5 million stock offering - Investing.com
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Vivos Therapeutics Secures $3.5M Financing Through Strategic Share Offering and Warrants - StockTitan
1.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):